Vemurafenib Instructions

1. Indications

Vemurafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma in whom the BRAF V600E mutation has been detected in an FDAapproved test.

Vemurafenib is indicated for the treatment of Erdheim-Chester disease patients with BRAF V600 mutations.

Restrictions on use: Vemurafenib is not indicated for the treatment of wild-type BRAF melanoma.

2. Dosage and usage

Before initiating vemurafenibtreatment, confirm the presence of BRAF V600Emutation in tumor specimens.

Recommended dose: 960mg twice daily, approximately 12 hours apart, with or without food.

Three. Dosage form and strength

Tablets: 240 mg.

Four. Contraindications

None

Five. Warnings and Precautions

1.New primary cutaneous malignancy:Perform dermatologic evaluation before initiating treatment, every 2 months during treatment, and up to 6 months after discontinuation of vemurafenib . Remove and continue treatment without dose adjustment.

2.New noncutaneous squamous cell carcinoma:Assess for symptoms or clinical signs of new noncutaneous squamous cell carcinoma before starting treatment and periodically during treatment.

3.Other malignant tumors:Close monitoring and acceptanceZELBORAFWhether the treated patient has signs or symptoms of other malignancies.

4.BRAFTumor-promoting effect of wild-type melanoma: BRAFinhibitors can increase cell proliferation.

5.Severe allergic reactions, including anaphylaxis and drug reactions, accompanied by eosinophilia and systemic symptoms (Dressing syndrome):Discontinue vemurafenib for severe allergic reactions.

6.Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis:Serious skin reactions should discontinue vemurafenib.

7.QTProlongation:Monitor ECG and electrolytes before and during treatment. Discontinue vemurafenib for QTc of 500 ms or greater. Correct electrolyte abnormalities and control cardiac risk factors for QT prolongation.

8.Hepatotoxicity: Measure liver enzymes and bilirubin before starting vemurafenib and monitor monthly during treatment.

9.Photosensitivity:Patients are advised to avoid sunlight exposure.

10.Severe Ophthalmic Reactions:Monitor for signs and symptoms of uveitis.

11.Embryo-Fetal Toxicity:Can cause fetal harm. Inform women of the potential risks to the fetus and use effective contraception.

12.Radiation allergy and radiation recalls:Serious cases have been reported.

13.Renal Failure:Measure serum creatinine before starting vemurafenib and monitor periodically during treatment.

14.DupuytrenContractures and Plantar Fascial Fibromatosis:Events should be managed by reducing dose, interrupting treatment, or discontinuing treatment.

6. Adverse reactions

Melanoma:The most common adverse reactions(≥ 30%) are joint pain, rash, alopecia, fatigue, photosensitivity, nausea, pruritus, and cutaneous papillomas.

Erdheim-Chester disease:The most common adverse reactions(> 50%)are arthralgia, maculopapular rash, alopecia, fatigue, ECGQT interval prolongation and cutaneous papilloma.

7. drug interactions

Avoid coadministration of vemurafenib with strong CYP3A4 inhibitors or inducers.

CYP1A2Substrates: Vemurafenib can increase the concentration of CYP1A2 substrates. Avoid coadministration of ZELBORAF with CYP1A2 substrates that have narrow therapeutic windows. If coadministration cannot be avoided, toxicity should be closely monitored and a dose reduction of the CYP1A2 substrate should be considered.

8. Use among specific groups of people

Lactation: Do not breastfeed while taking Vemurafenib .

Vemurafenib is an original drug available in Türkiye, with a retail price in pharmacies240 mg, 56 tablets2more than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0

xa0

xa0

xa0